- Applied DNA Sciences press release ( NASDAQ: APDN ): Q1 GAAP EPS of -$0.30 misses by $0.01 .
- Revenue of $5.26M (+26.1% Y/Y) beats by $1.09M .
- Included Orders for R&D Quantities of linearDNA™ from New Biopharma Customers.
- Maintains Timeline to cGMP Capacity, Initiates Build-out of Cost-Efficient Facility.
- Gross profit was $2.4 million, or 45%, compared to $1.1 million, or 27%, in the prior fiscal year period. The improvement in gross margin was primarily the result of an improved gross profit margin for our MDx testing service.
- Cash and cash equivalents stood at $12.9 million on December 31, 2022, compared with $15.2 million as of September 30, 2022.
For further details see:
Applied DNA Sciences GAAP EPS of -$0.30 misses by $0.01, revenue of $5.26M beats by $1.09M